Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages
Ilia N. Buhtoiarov(University of Wisconsin–Madison), Alexander L. Rakhmilevich(University of Wisconsin–Madison), Eric Yanke(University of Wisconsin–Madison), Paul M. Sondel(University of Wisconsin Carbone Cancer Center), Jon M. Wigginton(Johns Hopkins University), Tatiana Buhtoiarova(University of Wisconsin–Madison), David A. Mahvi(University of Wisconsin–Madison)
Cited by 142
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
|New England Journal of Medicine|2010|1.8k